News

First patient dosed in EVICTION trial evaluating ImCheck’s lead anti-cancer drug ICT01

Details

ImCheck Therapeutics has dosed the first patient in a Phase I/IIa clinical trial evaluating ICT01, a first-in-class gamma delta T cell-activatingmonoclonal antibody targeting the extracellular domain of Butyrophilin 3A. EVICTION (EValuation of ICT01 in Immuno-ONcology) is a first-in-human, two-part, open-label clinical trial to assess the safety, tolerability and activity of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced, relapsed/refractory cancer, including both solid and hematologic tumors that express BTN3A. 

Carisma Therapeutics: First-of-its-kind engineered macrophage cell therapy platform shows ability to reduce tumor burden & activate anti-tumor immunity, improving overall survival in pre-clinical cancer models

Details

Nature Biotechnology has published a study demonstrating Carisma's foundational technology evaluating the potential of human chimeric antigen receptor macrophages (CAR-M) for cancer immunotherapy. The preclinical findings indicate that CAR-M therapy could overcome the key challenges that cell therapies have encountered with solid tumors – limited trafficking to the tumor site, an immunosuppressive tumor microenvironment, and the heterogeneous expression of tumor-associated antigens. 

Karl Naegler joins Wellington Partners as Managing Partner

Details

Dr. Karl Naegler joined Wellington as a Managing Partner on January 1, 2020. Karl brings to Wellington a strong track record of investments in early and later stage life science companies as well as deep sector knowledge and an extensive global network from over 18 years of industry experience. 

  1. Wellington Partners participates in $53 Million Series B financing at ImCheck
  2. Wellington Partners participates in $100 Million Series B financing at eGenesis
  3. UroMems wins prestigious Prix Galien Med’Start-Up for best collaboration in the medtech or digital sector
  4. GTX medical & NeuroRecovery Technologies merge to create leading neurostimulation company for SCI
© Wellington Partners, 2020.